PSH.F - Sernova Corp.
Sernova Corp.
The Stiller Centre
Suite 114 700 Collip Circle
London, ON N6G 4X8
Canada
https://www.sernova.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees:
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Philip M. Toleikis B.A., M.Sc., Ph.D. | Pres, CEO & Director | 534k | N/A | N/A |
| Mr. David Swetlow C.A, C.A., CPA | Chief Financial Officer | 290.92k | N/A | N/A |
| Mr. Christopher Barnes | VP of Investor Relations | 121.31k | N/A | N/A |
| Dr. Frank Shannon M.D. | VP of Clinical Devel. & Regulatory Affairs | 238.67k | N/A | N/A |
| Mr. Douglas Maret | Chief Science Officer | N/A | N/A | N/A |
Description
Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and/or hormones for the long-term treatment of various serious chronic diseases, such as diabetes, hemophilia, and thyroid disease. Sernova Corp. has a research collaboration with AgeX Therapeutics, Inc. to generate immune-protected therapeutic cells;a research agreement with the University of Miami to advance the development of Cell Pouch cell therapy platform; and research collaboration with AstraZeneca PLC to evaluate novel potential therapeutic cell applications. The company was incorporated in 1998 and is headquartered in London, Canada.
Corporate Governance
Sernova Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
